Q2 EPS Forecast for Moleculin Biotech Increased by Analyst

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Analysts at Roth Capital upped their Q2 2025 EPS estimates for Moleculin Biotech in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.42) for the quarter, up from their prior forecast of ($0.46). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.77) EPS, FY2026 earnings at ($1.50) EPS, FY2027 earnings at ($1.44) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at $1.18 EPS.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.02. During the same period in the prior year, the company posted ($2.02) earnings per share.

Several other research analysts have also recently issued reports on the company. Maxim Group raised Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a report on Monday, March 24th. Finally, StockNews.com raised Moleculin Biotech to a “sell” rating in a report on Wednesday, March 26th.

Moleculin Biotech Trading Up 3.1%

NASDAQ MBRX opened at $0.94 on Friday. Moleculin Biotech has a one year low of $0.40 and a one year high of $5.15. The stock has a 50-day moving average of $0.98 and a 200 day moving average of $1.58.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC lifted its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,250,000 shares of the company’s stock after purchasing an additional 932,414 shares during the quarter. Armistice Capital LLC owned about 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent SEC filing. 15.52% of the stock is owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.